| Literature DB >> 33627983 |
Padma Rekha Jirge1, Sadhana Patwardhan2, Shishir Narendra Jirge1, Deepali A Bhomkar1, Shruti M Chougule1, Anita Salpekar2, Deepak Modi3.
Abstract
BACKGROUND: The pandemic of COVID-19 has affected many countries and medical services including assisted reproductive treatment (ART) have been hampered. AIM: The study was conducted to assess the preparedness of ART clinics and staff to resume services; patients' reasons to initiate treatment; and key performance indicators (KPIs) of ART laboratories during the pandemic. SETTING ANDEntities:
Keywords: Assisted reproduction; COVID-19 pandemic; SARS; coronaviruses; key performance indicators; resumption of in vitro fertilization
Year: 2020 PMID: 33627983 PMCID: PMC7879848 DOI: 10.4103/jhrs.JHRS_211_20
Source DB: PubMed Journal: J Hum Reprod Sci ISSN: 1998-4766
Figure 1Flow chart of the study design. ART=Assisted reproduction treatments, PPE=Personal protective equipment, LN2=Liquid nitrogen, IVF=In vitro fertilization, RIs=Reference indices, PIs=Performance indices, KPIs=Key performance indices
Time taken for resumption of services in the in vitro fertilization clinics postlockdown imposed due to COVID-19 pandemic
| Services | Time taken for re-initiation since lockdown |
|---|---|
| Laboratory preparedness | |
| LN2 supply | Uninterrupted |
| Calibrated CO2 cylinders | Already available |
| Daily logs | Uninterrupted |
| Availability of fresh culture media | 45 days |
| Availability of IVF laboratory consumables | 45 days |
| Availability of andrology laboratory consumables | 2 days |
| Establishing contact with equipment suppliers | 8 days |
| Availability of laboratory disinfectant | Continuous |
| Operation theater preparedness | |
| Availability of fresh stock of anesthetic medications | Uninterrupted |
| Availability of anesthetic gases | Uninterrupted |
| Consumables for routine procedures | Uninterrupted |
| Preparedness for superovulation | |
| Gonadotropins, agonists, and antagonists for superovulation | 30 days |
| Oral/transdermal estrogens; progesterone preparations | 7 days |
| COVID-19-specific preparedness | |
| Procuring N95 masks and other PPE | 7 days |
| Organizing the clinics for triage, isolation area, and patient movement | 2 days |
| Developing teleconsultation questionnaire | 1 day |
| Establishing teleconsultation system | 5 days |
| Sanitization of hospital every 4 h | Immediate |
| Staff preparation for COVID-19-specific requirements | |
| Number of staff willing to work | 31/32 (92.3%) |
| Number of staff eligible to work after completing triaging | 31 |
| Number of staff compliance with daily triage (since March 25, 2020) | 100% |
| Safe transport services for staff | 2 days |
| Staff compliance for wearing mask | Immediate |
| Compliance with hand sanitization | 2 days |
| Compliance with appropriate PPE | 7 days |
| Training for social distancing practices | 17 days |
| Training for obtaining patient consent for teleconsultation | 2 days |
CO2=Carbon dioxide, LN2=Liquid nitrogen, PPE=Personal protective equipment, IVF=In vitro fertilization
Outcomes of teleconsultation by the in vitro fertilization clinics after resumption of services postlockdown imposed due to COVID-19 pandemic
| Patient details | Number of couples, |
|---|---|
| Total number of couples administered with teleconsultation questionnaire | 169 |
| Number of couples agreeing to/eligible for treatment at teleconsultation | 52 (30.8) |
| Number of patients declining/advised against treatment at teleconsultation | 117 (69.2) |
| Reasons for declining | |
| Fear of pandemic | 11 (9.4) |
| Financial reasons | 24 (20.5) |
| Lack of access to clinic | 72 (61.5) |
| Presence of comorbidities | 9 (7.6) |
| Number of patients transferred to other clinics for accessibility | 1 (0.85) |
Indications for assisted reproduction in infertile couples who underwent treatment after resumption of services postlockdown imposed due to COVID-19 pandemic
| Indication for IVF | Number of couples ( |
|---|---|
| Fresh IVF cycles | 28 |
| Frozen embryo transfer cycles | 24 |
| Fertility preservation | 2 (3.8) |
| Age>35 years | 15 (28.8) |
| Poor ovarian reserve | 12 (23.1) |
| Severe male factor | 15 (28.8) |
| PCOS achieving desired weight reduction | 1 (1.9) |
| Couples’ choice (due to career) | 7 (13.5) |
PCOS=Polycystic ovarian syndrome, IVF=In vitro fertilization
Anesthesia and oocyte pick up details from both clinics after resumption of services postlockdown imposed due to COVID-19 pandemic
| Parameter | Protocol 1 | Protocol 2 | |
|---|---|---|---|
| Anesthesia used for OPU | CSA | GA | |
| Number of patients | 14 | 13 | |
| Duration of OPU (min) | 17.0±3.1 | 23.7±10.9 | 0.03* |
| Pain score during OPU as documented on a GRS | None: 1Mild: 12Moderate: 1 | - | - |
| Number of oocytes (mean±SD) | 12.6±7.4 | 14.5±7.5 | 0.5 |
*P=Significant; value is by Student’s t-test. CSA=Conscious sedation and analgesia, GA=General anesthesia, GRS=Graphic rating scale, OPU=Oocyte pick up, SD=Standard deviation
Reference/performance/key performance indicators in in vitro fertilization clinics after resumption of services postlockdown imposed due to COVID-19 pandemic
| Reference/performance/key performance indicators | Values during study period (%) | Historic data (%) | Competency value (Vienna consensus) | Benchmark value (Vienna consensus) |
|---|---|---|---|---|
| Time period | April 2020 - July 2020 | October 2019 - December 2019 | ||
| Number of patients | 52 | 117 | ||
| Reference indicators | - | |||
| Proportion of oocytes recovered | 366/389 (94.1) | 822/875 (93.9) | - | 80%-95% of follicles |
| Proportion of MII oocytes | 265/350 (75.7) | 503/670 (75.1) | - | 75%-90% |
| Performance indicators | ||||
| Postpreparation sperm motility | 90 | 90 | 90% | ≥95% |
| Polyspermy in IVF | 0/15 (0) | 5/152 (3.3) | - | <6% |
| 1 PN in IVF | 0/15 (0) | 6/152 (3.9) | - | <5% |
| 1 PN in ICSI | 3/265 (1.1) | 10/503 (1.9) | - | <3% |
| Good blastocysts | 40/82 (48.8) | 48/107 (44.8) | - | ≥40% |
| Key performance indicators | ||||
| ICSI damage rate | 25/285 (8.8) | 59/503 (11.7) | </=10 | </=5 |
| ICSI - normal fertilization | 187/285 (65.6) | 310/503 (61.6) | ≥65 | ≥80 |
| IVF - normal fertilization | 10/15 (66.7) | 98/152 (64.5) | ≥60 | ≥75 |
| Failed fertilization in IVF | 0 | 0 | <5 | |
| Cleavage rate | 87/93 (93.5) | 328/408 (80.3) | >/=95 | >/=99 |
| Day 2 embryo development rate | 63/93 (67.7) | 228/408 (55.3) | >/=50 | >/=80 |
| Day 3 embryo development rate | 134/197 (68) | 168/408 (41.1) | >/=40 | >/=60 |
| Blastocyst development rate | 73/156 (46.7) | 52/107 (48.5) | >/=40 | >/=60 |
| Implantation rate (day 3) | 2/6 (33.3)* | 18/70 (25.7) | >/=25 | >/=35 |
| Implantation rate (day 5) | 4/6 (66.6)* | 12/25 (48) | >/-35 | >/=60 |
| Blastocyst cryosurvival rate | 25/26 (96.2) | 50/52 (96.1) | >/=90 | /=99 |
| Implantation rate of vitrified and warmed embryos (day 5) | 12/25 (48) | 26/50 (52) | - | - |
*Data are from embryo transfer in fresh IVF/ICSI cycles. Values are expressed as numbers (%). ICSI=Intracytoplasmic sperm injection, IVF=In vitro fertilization, MII=Meiosis II, PN=Pronucleus